180633-56-1

Upstream product

• 92855-64-6 6-benzyloxy-1H-indole-3-carboxaldehyde 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 180633-64-1 (1-benzenesulfonyl-6-benzyloxy-1H-indol-3-yl)-[4-(1-benzenesulfonyl-1H-indol-3-yl)-1-benzyloxymethyl-1H-imidazol-2-yl]-methanone 
• 180633-62-9 (1-benzenesulfonyl-6-benzyloxy-1H-indol-3-yl)-(1-benzyloxymethyl-4-iodo-1H-imidazol-2-yl)-methanone 
• 180633-76-5 (6-benzyloxy-1H-indol-3-yl)-[1-benzyloxymethyl-4-(1H-indol-3-yl)-1H-imidazol-2-yl]-methanone 
• 112515-43-2 topsentin 
• 180633-60-7 (1-benzenesulfonyl-6-benzyloxy-1H-indol-3-yl)-(1-benzyloxymethyl-4-iodo-1H-imidazol-2-yl)-methanol 

Relevant academic research and scientific papers

Convenient access to bis-indole alkaloids. Application to the synthesis of?topsentins

Topsentins and related bis-indole alkaloids may be efficiently synthesized through an addition/oxidation sequence leading to 2-(3-indolylcarbonyl)-imidazole derivatives followed by a Pd-catalyzed heteroarylation with the appropriate 3-stannylindoles.

Fused [d]pyridazin-7-ones

The present invention is directed to fused [d]pyridazin-7-ones. The invention is also directed to methods for making and using the fused [d]pyridazin-7-ones. In particular, the compounds of the present invention may be effective in the treatment of diseases or disease states related to the activity of VEGFR2, MLK1 and CDK5 enzymes, including, for example, angiogenic disorders and neurodegenerative diseases.